Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety, tolerability, and pharmacokinetics of fidaxomicin in pediatric patients with Clostridium difficile-associated diarrhea (CDAD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile-associated Diarrhea

Drugs mentioned

• Fidaxomicin (fidaxomicin)

Snippet

Sponsor: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Clostridium Difficile-associated Diarrhea | Phase 2 | Status: COMPLETED | Results posted: 2015-03-17